Answers are grounded in this paper and cite their sources.
The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
No takes yet. Share an insight, caveat, or question.
Kant et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: